Department of Nutrition-Dietetics, Harokopio University
Athens, 17671, Greece
NCT Number: NCT04438122
Many epidemiological studies support that 20-30gr of alcohol consumption per day is related with lower risk for cardiovascular diseases, heart attack as well as mortality related to these diseases. Since the French paradox was reported, a number of experimental and clinical studies have demonstrated the protective effect of red wine compared to other alcoholic drinks on different pathways of the pathogenesis of atherosclerosis. The investigator's previous results revealed that wine contain micro-constituents that exert potent in vitro anti-platelet and anti-inflammatory actions. Also, the wine consumption along with a standardized meal reduced platelet aggregation and biosynthesis of Platelet Activating Factor in healthy men.
Although a large number of studies have reported protective effect of wine against atherosclerosis in healthy people there are few data about the effect of long-term moderate wine consumption in population with CVD. Therefore, the aim of this randomized, intervention clinical study, with control group was to report the effects of regular light to moderate wine consumption on cardiovascular biomarkers in people with CVD.
Looking for future studies?
Notify Me37 year–82 year
Male
Interventional
Not applicable
Athens, 17671, Greece
The study was a randomized, controlled, three-arm parallel intervention study, designed to evaluate if the light to moderate wine consumption could modulate thrombosis and inflammation, in patients with cardiovascular disease. The study was carried out in accordance with the guidelines laid down in the Declaration of Helsinki (1989) of the World Medical Association and was approved by the Bioethics Committee of Harokopio University. Seventy one men patients with cardiovascular disease were initially recruited to participate in the study. The recruitment took place in several hospitals of Athens in Greece under the supervisor of corresponding cardiologist. Finally 64 met the inclusion criteria. Prior to intervention all participants signed an informed consent All volunteers followed an initial 15 days wash-out period, abstaining from alcohol; then, they randomly assigned to one of the three intervention groups. The randomization code was prepared by a staff member who was not involved in running the trial, by using computer-generated random numbers. Subjects instructed to follow their usual diet and not change their medication during the study. In Group A (control group), participants consumed no alcohol, in Group B (ethanol group) participants consumed 69 mL of tsipouro with 38% alcohol and participants in Group C consumed 200ml of red wine (Cabernet Sauvignon 13.5% alcohol vol.). The ethanol that was consumed in the last two groups was equal at 27gr of ethanol per day and alcoholic beverage was consumed along with the meal (lunch or dinner). Finally, 57 participants completed the study, in particular 20 in Group A, 16 in Group B and 21 in Group C. Intervention lasted two months and biological samples (blood, urine) were collected at the beginning (0 week), in the middle (4 week) and in the end (8 week) of each intervention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The presence of Coronary Heart disease established by angiography or the presence of one of the following:
If nothing of the criteria above existed then hospitalization because of myocardial infarction or stroke.
Stable medication for at least 6 months.
Habit to drink 10-28gr of alcohol per week.
Exclusion criteria
History of any other inflammatory disease, diabetes, presence of cold or flu, acute respiratory infection, dental problems and renal/hepatic diseases.
Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
Tsipouro is a greek spirit which contains 38% alcohol vol
Time frame: Changes between baseline, 4 and 8 weeks.
% Change of EC50 value of platelet aggregation against PAF
Time frame: Changes between baseline, 4 and 8 weeks.
% Change of EC50 value of platelet aggregation against ADP
Time frame: Changes between baseline, 4 and 8 weeks.
% Change of EC50 value of platelet aggregation against collagen
Time frame: Changes between baseline, 4 and 8 weeks.
% Change in the activity of PAF biosynthetic enzyme Lyso-PAF AT
Time frame: Changes between baseline, 4 and 8 weeks.
% Change in the activity of PAF biosynthetic enzyme PAF-CPT
Time frame: Changes between baseline, 4 and 8 weeks.
% Change in the activity of PAF degradation enzyme PAF-AH
Time frame: Changes between baseline, 4 and 8 weeks.
% Change in the activity of PAF degradation enzyme Lp-PLA2
Time frame: Changes between baseline, 4 and 8 weeks.
% Changes of Adiponectin, IL-6, CRP
Time frame: Changes between baseline, 4 and 8 weeks.
Secretion of TNFa and IL-1β by PBMC under basal and inflammatory (LPS-induced) conditions at 4 and 24h incubation
Time frame: Changes between baseline, 4 and 8 weeks.
% Changes of VCAM, P-selectin.
Time frame: Changes between baseline, 4 and 8 weeks.
% Changes of Total cholesterol, LDL-chol, HDL-chol, triacylglycerols, uric acid, glucose, insulin, SGOT/AST, SGPT/ALT, γ-GT
Time frame: Changes between baseline, 4 and 8 weeks.
% Changes of TBARS, Lag time, GPx
Harokopio University
Other
Effect of Light to Moderate Wine Consumption on Cardiovascular Markers in Coronary Heart Disease Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738250
Cancer Survivorship, Cardiovascular Disease
View Trial DetailsNCT01778569
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02840448
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial Details